New Data from Accuray Highlights Long-Term Benefits of 5-Session Prostate Cancer Radiotherapy at ESTRO 2025
Accuray released new data on the benefits of the company’s CyberKnife® System in the treatment of prostate cancer at multiple stages of the cancer journey at the European Society for Radiotherapy and Oncology (ESTRO) meeting.
The studies, shared at the annual congress held in Vienna, Austria, indicate the system’s accuracy and precision enable treatment of high-risk disease, as well as recurrent prostate cancer following prostatectomy, with stereotactic body radiation therapy (SBRT), expanding access to a non-invasive, short course of care to more men.
Suzanne Winter, president and CEO of Accuray, stated, “At this year’s ESTRO meeting, important analyses of real-world evidence (RWE) underscored the benefits of our unique robotic and helical platforms, reaffirming their use as patients’ primary care option or along with other modalities such as surgery, chemotherapy or immunotherapy. Standout studies focused on the company’s CyberKnife System for the treatment of prostate cancer, building on a robust body of clinical data supporting its use and confirming the durability and quality of life after 10 years post-treatment. We’re grateful to the clinicians who continue to evaluate our technologies and advance personalized and precise care of patients through the work that they do.”
At ESTRO, Accuray hosted a symposium titled "Integrating Advanced Techniques in Genitourinary Radiotherapy: Harmonizing Precision, Personalization, and Efficacy," which drew an audience of 350 healthcare professionals. Leading international experts came together to discuss the latest advancements in radiotherapy for genitourinary cancers, including prostate, kidney, and bladder malignancies. Stereotactic body radiotherapy (SBRT) is increasingly recognized as a safe, effective alternative to traditional treatment options for localized prostate cancer, as patient care in these areas continues to evolve. Additionally, growing evidence supports the application of SBRT in the salvage setting for recurrent prostate cancer.
CyberKnife® Platform: Advancing Prostate Cancer Treatment
A retrospective analysis titled “Long-term outcomes and treatment efficacy in high-risk prostate cancer patients treated with stereotactic extreme hypofractionated radiotherapy” evaluated 262 men over the age of 70 or with significant comorbidities, all diagnosed with nonmetastatic high-risk or very high-risk prostate cancer. These patients were treated using the CyberKnife® System, receiving SBRT in just five sessions. With a median follow-up of 39 months, the study demonstrated that CyberKnife-based treatment offers a compelling therapeutic option, achieving favorable long-term outcomes while maintaining low rates of both acute and late urogenital (UG) and gastrointestinal (GI) toxicities.
Early results from a trial on stereotactic salvage radiotherapy for macroscopic prostate bed recurrence after prostatectomy: STARR (NCT05455736) is a prospective study evaluating the use of stereotactic salvage radiotherapy (SSRT) delivered with the CyberKnife System in five sessions. Androgen deprivation therapy was prohibited during SSRT. An early analysis of 51 patients with a median follow up of 16 months found that the CyberKnife System provides an effective and convenient option with mild toxicity for the treatment of recurrent cancer in the prostate bed following prostatectomy. The study investigators concluded, “Only mild toxicity was reported, underlining the safety of the treatment. Moreover, SSRT may be considered a convenient approach, considering the shorter treatment duration if compared to the standard approach.”